Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807308 | 0.93 | MAPT (0.44) | PLA2G4AMAPTPOLBLMNASMN1; SMN2 | |
| SCHEMBL2804337 | 0.86 | PLA2G4A (0.58) | PLA2G4AMAPTPOLB | |
| SCHEMBL2809726 | 0.85 | PLA2G4A (0.61) | PLA2G4A | |
| SCHEMBL2807125 | 0.85 | PLA2G4A (0.57) | PLA2G4AMAPTPOLB | |
| SCHEMBL2808266 | 0.78 | PLA2G4A (0.59) | PLA2G4AMAPTSMN1; SMN2 | |
| SCHEMBL2806883 | 0.77 | PLA2G2A (0.43) | PLA2G4AMAPTPOLBLMNASMN1; SMN2 | |
| SCHEMBL2804143 | 0.75 | MAPT (0.42) | PLA2G4AMAPTPOLBLMNASMN1; SMN2 | |
| SCHEMBL2806823 | 0.74 | PLA2G4A (0.54) | PLA2G4A | |
| SCHEMBL2806318 | 0.73 | PLA2G4A (0.58) | PLA2G4AMAPTPOLBTP53THRB | |
| SCHEMBL18930636 | 0.72 | LMNA (0.67) | MAPTPOLBLMNASMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2215059-A2 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | Westfälische Wilhelms-Universität Münster (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009040314-A2 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | Westfälische Wilhelms Universität Münster (DE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885MAPT 4523/4885POLB 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.